Suppr超能文献

我们在丙型肝炎微消除的正确轨道上吗?波兰透析中心的丙型肝炎管理实践——一项全国性横断面调查。

Are We on the Right Track for HCV Micro-Elimination? HCV Management Practices in Dialysis Centers in Poland-A National Cross-Sectional Survey.

作者信息

Czarnecka Paulina, Czarnecka Kinga, Tronina Olga, Baczkowska Teresa, Zarychta-Wisniewska Weronika, Durlik Magdalena

机构信息

Department of Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, Poland.

Department of Immunology, Transplant Medicine and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, Poland.

出版信息

J Clin Med. 2023 Apr 4;12(7):2711. doi: 10.3390/jcm12072711.

Abstract

Chronic hepatitis C (CHC) is prevalent in the hemodialysis-dependent population. Currently, all patients with CHC should be considered for treatment; however, many hemodialysis-dependent patients are still left untreated. Following HCV cure, accurate surveillance is mandatory to reduce liver-related mortality and prevent reinfection. We aimed to establish HCV management practices and barriers to HCV elimination in dialysis centers in Poland. Polish dialysis centers were surveyed via email. The HCV management strategies were investigated. Representatives of 112 dialysis centers responded, representing 43.1% of all dialysis centers in Poland and 43.4% of hemodialysis-dependent patients' volume. Most respondents were Heads of hemodialysis centers and board-certified nephrologists. The study demonstrated that in the vast majority of hemodialysis centers (91.6%), subjects are considered for antiviral treatment (AVT); however, many obstacles preventing patients from being prescribed AVT were identified; patients' reluctance to undergo AVT was most reported (60%). The majority of dialysis units neither evaluate patients with CHC for liver fibrosis (60.4%) nor screen them for hepatocellular carcinoma (53.5%). In conclusion, the presented study demonstrates that HCV management practices across Polish dialysis centers vary substantially. There is a need to optimize and streamline the HCV management infrastructure in the hemodialysis population in Poland.

摘要

慢性丙型肝炎(CHC)在依赖血液透析的人群中普遍存在。目前,所有CHC患者均应考虑接受治疗;然而,许多依赖血液透析的患者仍未得到治疗。丙肝治愈后,必须进行准确的监测,以降低肝脏相关死亡率并防止再次感染。我们旨在确定波兰透析中心的丙肝管理实践及消除丙肝的障碍。通过电子邮件对波兰透析中心进行了调查。对丙肝管理策略进行了研究。112个透析中心的代表做出了回应,占波兰所有透析中心的43.1%,以及依赖血液透析患者总量的43.4%。大多数受访者是血液透析中心主任和获得委员会认证的肾病专家。研究表明,在绝大多数血液透析中心(91.6%),患者会被考虑接受抗病毒治疗(AVT);然而,也发现了许多阻碍患者接受AVT治疗的障碍;最常被报告的是患者不愿接受AVT治疗(60%)。大多数透析单位既不评估CHC患者的肝纤维化情况(60.4%),也不对其进行肝细胞癌筛查(53.5%)。总之,本研究表明波兰各透析中心的丙肝管理实践差异很大。有必要优化和简化波兰血液透析人群的丙肝管理基础设施。

相似文献

2
Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.
Ther Apher Dial. 2023 Oct;27(5):831-838. doi: 10.1111/1744-9987.14003. Epub 2023 May 22.
3
Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan.
Am J Kidney Dis. 2021 Oct;78(4):511-519.e1. doi: 10.1053/j.ajkd.2021.03.017. Epub 2021 May 1.
5
The Seroprevalence of Hepatitis C Virus (HCV) in Hemodialysis Patients in Oman: A National Cross-Sectional Study.
J Epidemiol Glob Health. 2023 Dec;13(4):774-781. doi: 10.1007/s44197-023-00149-6. Epub 2023 Sep 12.
6
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy.
Clin Mol Hepatol. 2020 Jul;26(3):251-260. doi: 10.3350/cmh.2020.0018. Epub 2020 Mar 19.
7
Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study.
Clin Kidney J. 2023 Jun 14;16(12):2429-2436. doi: 10.1093/ckj/sfad138. eCollection 2023 Dec.
9
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Gastroenterol Hepatol. 2019 Mar;42(3):164-170. doi: 10.1016/j.gastrohep.2018.07.015. Epub 2018 Oct 4.
10
National surveillance of dialysis-associated diseases in the United States, 2002.
Semin Dial. 2005 Jan-Feb;18(1):52-61. doi: 10.1111/j.1525-139X.2005.18108.x.

本文引用的文献

3
Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?
Ren Fail. 2022 Dec;44(1):434-449. doi: 10.1080/0886022X.2022.2047069.
4
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415. doi: 10.1016/S2468-1253(21)00472-6. Epub 2022 Feb 16.
5
Updated Evidence on the Epidemiology of Hepatitis C Virus in Hemodialysis.
Pathogens. 2021 Sep 7;10(9):1149. doi: 10.3390/pathogens10091149.
7
Hepatitis C in Poland in 2018.
Przegl Epidemiol. 2020;74(2):209-222. doi: 10.32394/pe.74.17.
8
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184. doi: 10.1016/S2468-1253(18)30270-X.
9
When and how can nephrologists treat hepatitis C virus infection in dialysis patients?
Semin Dial. 2018 Jan;31(1):26-36. doi: 10.1111/sdi.12650. Epub 2017 Sep 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验